GlobeNewswire
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
➖
AI Sentiment
Neutral
5/10
- Home
- ALLO
as of 02-09-2026 4:00pm EST
$1.69
$0.00
0.00%
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 252.9M | IPO Year: | 2018 |
| Target Price: | $8.27 | AVG Volume (30 days): | 7.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.98 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.86 - $3.78 | Next Earning Date: | 03-12-2026 |
| Revenue: | N/A | Revenue Growth: | -76.84% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -158988000.0 | FCF Growth: | N/A |
AI-Powered ALLO Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 79.11%
79.11%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Allogene Therapeutics Inc. (ALLO)
Douglas Earl Martin
Sell
SVP, General Counsel
ALLO Feb 2, 2026
Avg Cost/Share
$1.76
Shares
22,900
Total Value
$40,304.00
Owned After
564,948
SEC Form 4
Parker Geoffrey M.
Sell
CHIEF FINANCIAL OFFICER
ALLO Feb 2, 2026
Avg Cost/Share
$1.76
Shares
24,001
Total Value
$42,241.76
Owned After
1,252,795
SEC Form 4
Chang David D
Sell
President and CEO
ALLO Feb 2, 2026
Avg Cost/Share
$1.80
Shares
95,269
Total Value
$171,484.20
Owned After
5,185,862
SEC Form 4
Roberts Zachary
Sell
EVP of R&D
ALLO Feb 2, 2026
Avg Cost/Share
$1.77
Shares
35,700
Total Value
$63,189.00
Owned After
581,166
SEC Form 4
Yoshiyama Annie
Sell
SVP, Finance
ALLO Feb 2, 2026
Avg Cost/Share
$1.72
Shares
4,167
Total Value
$7,167.24
Owned After
130,322
SEC Form 4
Beneski Benjamin Machinas
Sell
SVP, Chief Technical Officer
ALLO Feb 2, 2026
Avg Cost/Share
$1.73
Shares
7,549
Total Value
$13,059.77
Owned After
210,172
SEC Form 4
Roberts Zachary
Sell
EVP of R&D
ALLO Jan 21, 2026
Avg Cost/Share
$1.56
Shares
26,269
Total Value
$40,979.64
Owned After
581,166
SEC Form 4
Beneski Benjamin Machinas
Sell
SVP, Chief Technical Officer
ALLO Nov 17, 2025
Avg Cost/Share
$1.22
Shares
786
Total Value
$958.92
Owned After
210,172
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Douglas Earl Martin | ALLO | SVP, General Counsel | Feb 2, 2026 | Sell | $1.76 | 22,900 | $40,304.00 | 564,948 | |
| Parker Geoffrey M. | ALLO | CHIEF FINANCIAL OFFICER | Feb 2, 2026 | Sell | $1.76 | 24,001 | $42,241.76 | 1,252,795 | |
| Chang David D | ALLO | President and CEO | Feb 2, 2026 | Sell | $1.80 | 95,269 | $171,484.20 | 5,185,862 | |
| Roberts Zachary | ALLO | EVP of R&D | Feb 2, 2026 | Sell | $1.77 | 35,700 | $63,189.00 | 581,166 | |
| Yoshiyama Annie | ALLO | SVP, Finance | Feb 2, 2026 | Sell | $1.72 | 4,167 | $7,167.24 | 130,322 | |
| Beneski Benjamin Machinas | ALLO | SVP, Chief Technical Officer | Feb 2, 2026 | Sell | $1.73 | 7,549 | $13,059.77 | 210,172 | |
| Roberts Zachary | ALLO | EVP of R&D | Jan 21, 2026 | Sell | $1.56 | 26,269 | $40,979.64 | 581,166 | |
| Beneski Benjamin Machinas | ALLO | SVP, Chief Technical Officer | Nov 17, 2025 | Sell | $1.22 | 786 | $958.92 | 210,172 |
Latest Allogene Therapeutics Inc. News
ALLO Breaking Stock News: Dive into ALLO Ticker-Specific Updates for Smart Investing
Simply Wall St.
Allogene Therapeutics (ALLO) Is Up 24.1% After Extended Cash Runway and CAR T Trial Progress
📈
AI Sentiment
Highly Positive
8/10
Compare ALLO vs Leading Stocks
See how ALLO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ALLO Allogene Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.